Can-Fite BioPharma Ltd.
Namodenoson
pancreatic cancer
Resolved
68days ago
Phase 2 readout · Apr 30, 2026
What's at stake
Phase 2 trial results for Namodenoson in pancreatic cancer are due Apr 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“A Phase IIb MASH study is currently enrolling patients and is designed to evaluate effects on inflammation, fibrosis, steatosis, and body weight.”